{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:00:30Z","timestamp":1771304430061,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s15010-021-01618-5","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T12:03:56Z","timestamp":1620129836000},"page":"945-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multicentric Castleman\u2019s disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018"],"prefix":"10.1007","volume":"49","author":[{"given":"Smaranda","family":"Gliga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Martin","family":"Orth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn-Erik Ole","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"1618_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM195406102502308","volume":"250","author":"B Castleman","year":"1954","unstructured":"Castleman B, Towne VW. Case records of the Massachusetts General Hospital: case no. 40231. N Engl J Med. 1954;250:1001\u20135.","journal-title":"N Engl J Med."},{"key":"1618_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ijc.28923","volume":"137","author":"A Carbone","year":"2015","unstructured":"Carbone A, De Paoli P, Gloghini A, Vaccher E. KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies. Int J Cancer. 2015;137:251\u201361.","journal-title":"Int J Cancer"},{"key":"1618_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1309\/AJCPV1I2QWKZKNJH","volume":"136","author":"ED His","year":"2011","unstructured":"His ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol. 2011;136:183\u201394.","journal-title":"Am J Clin Pathol"},{"key":"1618_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12273","volume":"17","author":"I-U Haq","year":"2016","unstructured":"Haq I-U, Pria AD, Papanastasopoulos P, Stegmann K, Bradshaw D, Nelson M, Bower M. The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients. HIV Med. 2016;17:56\u201361.","journal-title":"HIV Med"},{"key":"1618_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","volume":"86","author":"J Soulier","year":"1995","unstructured":"Soulier J, Grollet L, Oksenhendler E, et al. Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman\u2019s disease. Blood. 1995;86:1276\u201380.","journal-title":"Blood"},{"key":"1618_CR6","first-page":"25","volume":"10","author":"EE Mylona","year":"2008","unstructured":"Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman\u2019s disease in HIV infection: a systematic review of the literature. AIDS. 2008;10:25\u201335.","journal-title":"AIDS"},{"key":"1618_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1258\/ijsa.2011.010464","volume":"22","author":"R Sayer","year":"2011","unstructured":"Sayer R, Paul J, Tuke PW, Hargreaves S, Noursadeghi M, Tedder RS, Grant P, Edwards SG, Miller RF. Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma? Int J STD AIDS. 2011;22:585\u20139.","journal-title":"Int J STD AIDS"},{"key":"1618_CR8","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"N Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627\u201332.","journal-title":"Blood"},{"key":"1618_CR9","first-page":"9","volume":"10","author":"JL Koff","year":"2016","unstructured":"Koff JL, Lonial S. Emerging treatments in Castleman disease - a critical appraisal of siltuximab. Biologics. 2016;10:9\u201315.","journal-title":"Biologics"},{"key":"1618_CR10","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","volume":"19","author":"R Kurzrock","year":"2013","unstructured":"Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19:3659\u201370.","journal-title":"Clin Cancer Res"},{"key":"1618_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1756-8722-7-10","volume":"7","author":"A Nagao","year":"2014","unstructured":"Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol. 2014;7:10.","journal-title":"J Hematol Oncol"},{"key":"1618_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","volume":"147","author":"M Bower","year":"2007","unstructured":"Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147:836\u20139.","journal-title":"Ann Intern Med"},{"key":"1618_CR13","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1182\/blood-2011-02-333633","volume":"118","author":"C Hoffmann","year":"2011","unstructured":"Hoffmann C, Schmid H, M\u00fcller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, J\u00e4ger H, Bogner J, Arasteh K. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118:3499\u2013503.","journal-title":"Blood"},{"key":"1618_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ajh.20418","volume":"79","author":"S Neuville","year":"2005","unstructured":"Neuville S, Agbalika F, Rabian C, Briere J, Molina JM. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol. 2005;79:337\u20139.","journal-title":"Am J Hematol"},{"key":"1618_CR15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/QAD.0b013e3282f7371f","volume":"22","author":"T Buchler","year":"2008","unstructured":"Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV\/human herpesvirus 8-associated Castleman\u2019s disease with multiorgan failure: report of two cases. AIDS. 2008;22:1685\u20137.","journal-title":"AIDS"},{"key":"1618_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00002030-199601000-00009","volume":"10","author":"E Oksenhendler","year":"1996","unstructured":"Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman\u2019s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61\u20137.","journal-title":"AIDS"},{"key":"1618_CR17","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","volume":"116","author":"M Bower","year":"2010","unstructured":"Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116:4415\u201321.","journal-title":"Blood"},{"key":"1618_CR18","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2016-10-747477","volume":"129","author":"AD Pria","year":"2017","unstructured":"Pria AD, Pinato D, Roe J, Naresh K, Nelson M, Bower M. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. Blood. 2017;129:2143\u20137.","journal-title":"Blood"},{"key":"1618_CR19","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1182\/blood-2011-08-376012","volume":"119","author":"L G\u00e9rard","year":"2012","unstructured":"G\u00e9rard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012;119:2228\u201333.","journal-title":"Blood"},{"key":"1618_CR20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/02841860410002752","volume":"43","author":"A Waterston","year":"2004","unstructured":"Waterston A, Bower M. Fifty years of multicentric Castleman\u2019s disease. Acta Oncol. 2004;43:698\u2013704.","journal-title":"Acta Oncol"},{"key":"1618_CR21","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1097\/QAI.0b013e3182a8338f","volume":"65","author":"M Bower","year":"2014","unstructured":"Bower M, Pria AD, Coyle C, Nelson M, Naresh K. Diagnostic criteria schemes for multicentric Castleman disease in 75 cases. J Acquir Immune Defic Syndr. 2014;65:e80\u20132.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1618_CR22","unstructured":"Hoffmann C, Rockstroh J.K. (2018) HIV 2018\/2019. Medizin Fokus Verlag, pp 412\u201320"},{"key":"1618_CR23","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1200\/JCO.2010.34.1909","volume":"29","author":"M Bower","year":"2011","unstructured":"Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman\u2019s disease. J Clin Oncol. 2011;29:2481\u20136.","journal-title":"J Clin Oncol"},{"key":"1618_CR24","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.2147\/CMAR.S175648","volume":"10","author":"ER Mahroug","year":"2018","unstructured":"Mahroug ER, Sher-Locketz C, Desmirean MS, Abayomi EA, Tomuleasa C, Grewal R. Castleman\u2019s disease in the HIV-endemic setting. Cancer Manag Res. 2018;10:4553\u201363.","journal-title":"Cancer Manag Res"},{"key":"1618_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/annonc\/mdn697","volume":"20","author":"T Powles","year":"2009","unstructured":"Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman\u2019s disease. Ann Oncol. 2009;20:775\u20139.","journal-title":"Ann Oncol"},{"key":"1618_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1468-1293.2004.00204.x","volume":"5","author":"S Loi","year":"2004","unstructured":"Loi S, Goldstein D, Clezy K, Milliken ST, Hoy J, Chipman M. Castleman\u2019s disease and HIV infection in Australia. HIV Med. 2004;5:157\u201362.","journal-title":"HIV Med"},{"key":"1618_CR27","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood.V96.6.2069.h8002069_2069_2073","volume":"96","author":"E Oksenhendler","year":"2000","unstructured":"Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96:2069\u201373.","journal-title":"Blood"},{"key":"1618_CR28","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","volume":"122","author":"MN Polizzotto","year":"2013","unstructured":"Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O\u2019Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013;122:4189\u201398.","journal-title":"Blood"},{"key":"1618_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000455971","volume":"40","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Sabranski M, Esser S. HIV-associated Kaposi\u2019s sarcoma. Oncol Res Treat. 2017;40:94\u20138.","journal-title":"Oncol Res Treat"},{"key":"1618_CR30","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","volume":"124","author":"TS Uldrick","year":"2014","unstructured":"Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124:3544\u201352.","journal-title":"Blood"},{"key":"1618_CR31","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12:614704.","journal-title":"Front Immunol"},{"key":"1618_CR32","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1182\/blood.2019002792","volume":"135","author":"DJ Arenas","year":"2020","unstructured":"Arenas DJ, Floess K, Kobrin D, Pai RL, Srkalovic MB, Tamakloe MA, Rasheed R, Ziglar J, Khor J, Parente SAT, Pierson SK, Martinez D, Wertheim GB, Kambayashi T, Baur J, Teachey DT, Fajgenbaum DC. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood. 2020;135:1673\u201384.","journal-title":"Blood"},{"key":"1618_CR33","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.4049\/jimmunol.164.9.4672","volume":"164","author":"J M\u00fcllberg","year":"2000","unstructured":"M\u00fcllberg J, Geib T, Jostock T, Hoischen SH, Vollmer P, Voltz N, Heinz D, Galle PR, Klouche M, Rose-John S. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol. 2000;164:4672\u20137.","journal-title":"J Immunol"},{"key":"1618_CR34","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","volume":"117","author":"TS Uldrick","year":"2011","unstructured":"Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117:6977\u201386.","journal-title":"Blood"},{"key":"1618_CR35","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood.V99.7.2331","volume":"99","author":"E Oksenhendler","year":"2002","unstructured":"Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331\u20136.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1007\/s15010-021-01627-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-021-01618-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T03:14:42Z","timestamp":1744082082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-021-01618-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s15010-021-01618-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s15010-021-01627-4","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-021-01627-4","URL":"https:\/\/doi.org\/10.1007\/s15010-021-01627-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}